Oxidative stress has been increasingly linked to the high incidence of cardiovascular events in patients with chronic kidney disease (CKD), especially as traditional cardiovascular risk factors seem to not be able to account for the huge cardiovascular morbidity and mortality in this population group. Oxidative stress is increased in patients with renal impairment as a result of increased oxidant activity and reduced antioxidant capacity, and this is increased in a graded manner with increasing renal dysfunction. Inflammation, which is also present in CKD, further amplifies the oxidant generation process. The two clinical sequelae of oxidative stress are endothelial dysfunction and left ventricular hypertrophy, which have adverse cardiovascular consequences. With our new understanding of oxidative stress, it is now important to assess treatment options that reduce it in the hope that they reverse endothelial dysfunction and left ventricular hypertrophy and the clinical sequelae of these abnormalities.
Introduction
Chronic kidney disease (CKD) is a growing public health problem globally, with rising incidence and prevalence. In the United States alone, it is estimated that approximately 8 million adults have at least stage 3 CKD (defined as glomerular filtration rate of less than 60 ml min -1 per 1.73 m 2 of body surface area), 1 and more than 400 000 adults have end-stage renal disease (ESRD), with over 300 000 of them on maintenance dialysis. 2 The annual mortality of ESRD patients approaches 9% per year, which is 10-to 20-fold higher than that in the general population, even after stratification for factors such as age and diabetes, 3 and approximately half of these deaths have been attributable to cardiovascular disease. 4 The aetiology of cardiovascular disease in CKD is complex. It may partly be a result of increased prevalence of classic cardiovascular risk factors. Although CKD is strongly associated with risk factors for atherosclerosis, the excessive high cardiovascular risk seen in this cohort of patients is not fully accounted for by traditional cardiovascular risk factors. 5 A part of the extra risk is also attributable to renal-specific risk factors, related to uraemia or dialysis. These extra renal risk factors include proteinuria, increased renin-angiotensin system activity, chronic volume overload, altered calcium and phosphorus metabolism, inflammation, infection, anaemia, malnutrition, oxidative stress, elevated levels of homocysteine, uraemic toxins and thrombogenic factors. Some of these latter extra risk factors may act by producing accelerated atherogenesis. One particular example of an extra risk factor that may accelerate atherogenesis is oxidative stress, which probably makes a significant contribution to the excess cardiovascular burden in CKD patients. In fact, oxidative stress may actually represent a new target for therapeutic intervention. 6 In this review, we aim at focusing on oxidative stress in CKD. We will first address the factors involved in the genesis of oxidative stress in general. Second, we aim at addressing why oxidative stress is elevated in patients with CKD. Third, we will discuss the detrimental effect that oxidative stress may have in patients with renal dysfunction. Finally, we present available evidence on pharmacological agents that inhibit oxidative stress and which may therefore have potential for improving cardiovascular outcomes in this patient population. A literature search was conducted through Pubmed, using the keywords oxidative stress, kidney disease, endothelial dysfunction and left ventricular hypertrophy. The search was limited to English journals with additional specific enquiries regarding certain selected articles mentioned in the bibliography of those yielded by the search.
Oxidative stress: what is it?
Oxidative stress is a term first described by Seis in 1985. 7 Oxidative stress is defined as the tissue damage resulting from an imbalance between an excessive generation of oxidant compounds and insufficient antioxidant defence mechanisms. Generation of oxidative compounds is physiologically important as part of a defence mechanism against invading microorganisms or malignant cells, as well as of tissue repair, healing and remodelling. 6 However, an 'inappropriate' activation of oxidative stress may result in vascular injury and in the progression of atherosclerosis. This amplification of atherosclerosis occurs mainly by direct oxidative damage of cellular components, leading to defective cellular function, ageing and apoptosis by activation of signalling pathways. 8 Oxidant compounds such as reactive oxygen species (ROS) and reactive nitrogen species are called reactive because of their unstable nature and the way they interact with their surrounding molecules. Evidence suggests that both vascular and nonvascular enzymes can generate ROS, and that nicotinamide adenine dinucleotide phosphate (NADPH) oxidase in particular has a major role in their generation. In addition, lipoxygenase, xanthine oxidase, uncoupled nitric oxide synthase and a dysfunctional mitochondrial respiratory chain can produce oxidative stress. 9, 10 The release of one ROS may lead to the production of several others through radical chain reactions. ROS is generated through a univalent reduction of oxygen (O 2 ) . After exposure to stimuli, both polymorphonuclear neutrophils and monocyte-macrophages are activated and, as a result, increase their O 2 consumption ('respiratory burst'). 6 This O 2 will then be reduced to superoxide anion (O 2 À ) by the NADPH-oxidase enzyme system. O 2 À will then be converted into hydrogen peroxide (H 2 O 2 ), which is highly unstable, either by dismutation of O 2 À or by direct reduction of O 2 . Importantly, both O 2 À and H 2 O 2 will go on to be precursors for the generation of more powerful oxidants. 11 Increased production of all these oxidants inactivates nitric oxide (NO), resulting in reduced bioavailability of NO. They also lead to the formation of peroxynitrite, which is not only cytotoxic but it is also responsible for both increased platelet aggregation and vasoconstriction. O 2 À interacts with NO to form highly toxic nitrogen derivatives, whereas H 2 O 2 reacts with intracellular iron to form hydroxyl radicals (OH À ).
11 These then exert a pivotal effect in the degradation process of the cell membrane lipid, as well as in protein aggregation and DNA damage. H 2 O 2 is also the substrate for myeloperoxidase to produce chlorinated oxidants such as hypochlorous acid, another potent oxidant, especially in molecules such as lipids, proteoglycans and other intracellular components. Experiments have also shown that oxidative stress and subclinical inflammation coexist together. When released together with proinflammatory cytokines, angiotensin II and advanced glycation end products, ROS release will obviously augment the whole ROS generation process. 12 Evaluation of oxidative stress in a clinical setting is difficult because free radicals have very short halflives (in seconds). In contrast, there are actual, more stable marker molecules that have longer half-lives, ranging from hours to weeks, which can be used to assess oxidative stress. These include molecules derived from lipid peroxidation, and a list of these markers is given in Table 1 . For example, F 2 -isoprostane, which is a nonenzymatic, free radical-catalysed isomer of cyclooxygenase-derived enzymatic products of arachidonic acid, can be found in both urine and plasma. 13 It is a stable end product of arachidonic acid oxidation and can be measured with high sensitivity and specificity. 14 To counteract the damaging effects of these oxidants, endogenous antioxidant defence mechanisms are in place. There are two lines of enzymatic and nonenzymatic antioxidant defence within the cell. The first line, found in the fat-soluble cellular membrane consists of vitamin E, b-carotene and coenzyme Q. Of these, vitamin E is considered the most potent, as it protects the cell membrane by reacting with lipid radicals, removing intermediate free radicals in the process. The second line is made of hydrophilic water-soluble antioxidant scavengers, which include vitamin C, glutathione peroxidise, superoxide dismutase and catalase. Superoxide dismutase, which represents a first line defence against oxidative attack, converts O 2 À to H 2 O 2 , and then catalase reduces H 2 O 2 to water. 6 As for Vitamin C, it particularly protects plasma lipids from peroxidation, scavenges superoxide anion and has a role in Oxidative stress in CKD MPC Kao et al recycling vitamin E. 15 The list of both enzymatic and nonenzymatic antioxidants is given in Table 1 .
Oxidative stress: is it important in renal dysfunction?
Earlier studies have shown a significant imbalance in pro-oxidant and antioxidant activities in patients with renal dysfunction. 16, 17 In fact, oxidative stress has been found even in the early stages of CKD, as reflected by plasma 8-isoprostane levels. Furthermore, oxidative stress seems to increase as CKD progresses and correlates significantly and inversely with the level of glomerular filtration rate. 18 WitkoSarsat et al. and Terawaki et al. 19, 20 also found the same, using other markers of oxidative stress (malonyldialdehyde and glutathione peroxidase, and oxidized serum albumin, respectively).
Indirect confirmation that oxidative stress is especially important in renal dysfunction comes from several main studies. First, exogenous antioxidant vitamins have been tried in many large, randomised trials in the general population, such as the Heart Protection Study and Heart Outcomes and Prevention Evaluation study, but all of these trials in non-CKD patients were negative. 21, 22 However, the Secondary Prevention with Antioxidants of Cardiovascular Disease in End-stage Renal Disease (SPACE) trial, which used high-dose oral vitamin E in a cohort of haemodialysis (HD) patients with a history of cardiovascular disease, found that vitamin E significantly reduced cardiovascular events. 23 The uniquely positive results from the Secondary Prevention with Antioxidants of Cardiovascular Disease in End-stage Renal Disease trial suggest that oxidative stress is a more important cardiovascular culprit in renal disease than in others. Second, results of the Prevention of Events with Angiotensin-Converting Enzyme Inhibition trial also support the hypothesis that oxidative stress is particularly adverse in patients with CKD because the angiotensin-converting enzyme inhibitor, Trandolapril (Abbott Laboratories, Abbott Park, IL, USA), was found to reduce all-cause mortality only in those with a glomerular filtration rate o60 ml min -1 per 1.73 m 2 , but not in those with a preserved renal function. 24 The importance of this analysis is that angiotensinconverting enzyme inhibitors are thought to produce part of their benefit by inhibiting angiotensin IIdependent NADPH oxidase, which is a key source of oxidative stress in the body. Finally, a recent randomised controlled trial showed that a group of HD patients randomised to oral acetylcysteine (antioxidant) 600 mg bd, when compared with placebo, had a lower incidence of the primary end point, which was a composite of fatal and non-fatal myocardial infarction, cardiovascular disease death, need for coronary angioplasty or coronary artery bypass, ischaemic stroke, peripheral vascular disease and unstable angina. 25 Why is there an excess of oxidative stress in patients with renal dysfunction? Different mechanisms could explain this increased oxidative stress in CKD. Basic characteristics of renal patients such as advanced age, diabetes and renal hypertension would predispose them to increasing levels of oxidative stress compared with the general population. Renal disease patients, especially those at end stage, with their dietary restriction of fresh fruits and vegetables (to avoid hyperkalaemia), would also have lower levels of vitamin C. 6 Each HD session induces oxidative stress, with ROS being generated on the surface of dialysis membranes by the activation of polymorphonuclear neutrophils due to bioincompatibility, while causing concomitant loss of antioxidant vitamins through the dialysis process itself. Peuchant et al. and Jackson et al. 26, 27 showed that even a single HD session significantly increases lipid peroxides and decreases antioxidants. Furthermore, it has been shown that there is a parallel increase in oxidative stress with increasingly longer durations of HD sessions. 28 Spittle et al. 29 have shown a higher level of F 2 -Isoprostane, a marker of oxidative stress, in patients undergoing HD. We know from earlier studies that plasma selenium is reduced and there is significant deficiency in glutathione peroxidise scavenging system concentrations in patients on HD. 30, 31 In fact, one study has shown increased levels of glutathione peroxidise and superoxide dismutase in patients with CKD, as a protective antioxidant mechanism, but this was abolished once they were on maintenance HD. 31 Plasma vitamin E concentrations have also been shown to be lower, but its inefficiency to protect low-density lipoprotein (LDL) particles against oxidation in patients with CKD may also be because of an alteration of its function resulting from vitamin C deficiency. Other antioxidant defence mechanisms such as copper-zinc superoxide dismutase and manganese superoxide dismutase have also been shown to be downregulated in patients with renal dysfunction. 32 Inflammation is another important cause for the increased oxidative stress observed in patients with advanced renal disease, with factors such as malnutrition, chronic volume overload and autonomic dysfunction being among some of the factors implicated in the increased inflammatory state seen in renal impairment. Activation of polymorphonuclear neutrophils is a well-recognised feature in CKD patients, with documented association between renal dysfunction and the different mediators and markers of inflammation such as CRP, IL-6, TNF-a and fibrinogen, suggesting that CKD is a lowgrade inflammatory process in itself. 28 Myeloperoxidase is generated in response to activation of polymorphonuclear neutrophils, and this should trigger ROS activation and inactivation of NO. In a recent study, serum myeloperoxidase was found to be associated with markers of both inflammation and mortality in HD patients. 33 
Clinical consequences of oxidative stress in renal dysfunction
Excessive production of ROS is a major cause of endothelial dysfunction (Figure 1 ). LDL-cholesterol molecules are easily oxidised when oxidative stress is present. These oxidised LDL molecules attack the arterial intima readily and are also highly atherogenic, triggering an inflammatory response in the vessel. They induce the expression of leukocyte adhesion molecules and subsequent binding of circulatory inflammatory cells and their migration into the subendothelial space. The outcomes of these are endothelial dysfunction, platelet aggregation, metaloproteinase expression and thrombogenesis. With progressive accumulation of oxidised LDL, macrophages modulate their phenotype, turning them into foam cells. Foam cells are the principal component of fatty streaks, which is the first step in atheromatous plaque formation, and they trigger antigenic reaction in T-lymphocytes that will either initiate or increase the immunological response. 34 Several qualitative LDL changes have been shown to occur in dialysis patients. These include increased carbamylation and advanced glycation end products transformation and oxidation, all of which promote the development of atherosclerosis. 35 Further evidence supporting excessive oxidation includes increased levels of circulating lipid peroxidation markers such as malondialdehyde and conjugated diene, 36 as well as the presence of oxidised LDL and elevated levels of antioxidised antibodies. 37 We also know that the normal equilibrium between NO formation and ROS is disrupted in atherosclerosis. NO is an antioxidant on its own, inhibiting the activation of xanthine oxidase and NADPH oxidase, while maintaining normal O 2 -/NO homeostasis. Hence, with more NO being converted into peroxynitrite, this leads to a loss of normal NO, which compromises endothelial function.
Impairment of endothelial function is an early indicator of atherosclerosis, as described in the mechanisms above. Studies have shown that it is an independent predictor of cardiovascular events, including myocardial infarction, unstable angina, ischaemic stroke, heart failure and death, and is also associated with restenosis after coronary interventions. 38 Furthermore, endothelial dysfunction can be measured in peripheral arteries as a surrogate for coronary circulation, using methods such as venous occlusive pletysmography, vascular tonometry and brachial artery ultrasound using flow-mediated dilatation. It is also reversible and its improvement could reflect decreased cardiovascular risk. Endothelial dysfunction is especially important in renal disease, given the nature of accelerated atherosclerosis in them. It differs from the general population in that vascular calcification is much more pronounced, and the efficacy of standard treatments, such as statins, although well established in the general population, has so far been unconvincing in the dialysis and transplanted population. [39] [40] [41] In a recent meta-analysis, although statins significantly reduced all-cause mortality by 19% in the pre-dialysis population, they have produced no significant risk reduction in dialysis and transplant patients. 42 The second and less well-appreciated adverse cardiovascular consequence of oxidative stress is the development of left ventricular hypertrophy (LVH). In CKD patients, the estimates of LVH prevalence vary between 40 and 75%, depending on the severity of renal dysfunction. 43, 44 The adverse association between LVH and clinical outcomes is well documented and shall be addressed later on. The precise aetiology of LVH in this patient population is likely to be multi-factorial, although wellknown traditional risk factors such as hypertension and volume loading conditions (for example, in dialysis-dependent patients) have an important role. Nevertheless, there is emerging evidence to also suggest that oxidative stress has a pivotal role in the progression of left ventricular mass in CKD patients. In vivo studies have shown overwhelming evidence that oxidative stress triggers cardiomyocyte hypertrophy, whereby ROS activates a broad variety of hypertrophy signalling kinases (tyrosine kinase Src, GTP-binding protein Ras, protein kinase C, mitogenactivated protein kinase and Jun-nuclear kinase) and transcription factors (kB, Ets and activator-protein-1), Oxidative stress in CKD MPC Kao et al which stimulate matrix metalloproteinases expression. 45 ROS also has a major role in G proteincoupled hypertrophic stimulation by angiotensin II and a-adrenergic stimulation. 45, 46 Furthermore, ROS is also found to stimulate cellular apoptosis. Activation of apoptosis signalling kinase-1 will activate nuclear factor kB, which is implicated in cardiomyocyte hypertrophy. 47 In addition to all the above, ROS also has a role in stimulating cardiac fibroblast proliferation and in activating metalloproteinases in the extracellular matrix, effects shown in fibrosis and matrix remodelling. 48 Several studies have implicated NADPH oxidase as one of the main sources of oxidative stress that caused the hypertrophic phenotype, although one study also implicates xanthine oxidase as another culprit. 49, 50 In addition, ROS seems to mediate the hypertrophic response to other known hypertrophic stimuli. 45, 46, 51 Hence, a vicious cycle is created, whereby pressure overload produces oxidative stress, which in turn exacerbates the hypertrophic response to this pressure overload. Of course pressure overload is almost universal in CKD, because of extracellular volume expansion, increased sympathetic activity, elevated endothelin production, enhanced local and systemic renin-angiotensin system activity and accumulation of Na-K-ATPase inhibitors and Ca 2 þ -ATPase inhibitors. This in vitro work is corroborated by much in vivo work in experimental models of pressure overload.
In the endothelium, generation of NO from L-arginine is controlled by NO synthase (NOS), and tetrahydrobiopterin (BH 4 ) is an essential factor for NOS formation and stability of the oxidase domain. BH 4 is required to maintain NO in its 'coupled' state to keep generating 'good' NO. 6 When BH 4 gets oxidised, NOS functions as an oxidising agent itself and instead of generating 'good' NO, it generates superoxide anion, amplifying oxidative stress further. 46 This uncoupling of NOS has been implicated in the endothelial dysfunction seen in hypertension, diabetes, smoking and atherosclerosis. [52] [53] [54] [55] However, recent evidence suggests that it also has an important role in adverse remodelling in chronic pressure overload of the heart. 56 Oxidative stress is known to inactivate endogenous NO and many studies now clearly show that experimental NO deficiency can in itself exacerbate LVH, even in tissue culture in which hypertrophy could not be due to haemodynamic loading. 57 Left ventricular hypertrophy is of particular relevance as a risk factor in CKD. From the Framingham study, we know that LVH is an independent predictor of cardiovascular mortality, and in fact it is said to be the strongest predictor of cardiovascular events and death after age. 58 The mechanisms for the adverse effects of LVH are complex. First, LVH is intrinsically arrhythmogenic, predisposing patients to ventricular arrhythmias. 59 Second, it reduces coronary flow reserve while increasing myocardial oxygen consumption. 60 Third, LVH is strongly associated with diastolic dysfunction, which is the precursor to developing diastolic heart failure. 61 Finally, it predisposes patients to left atrial dilatation, which is a wellknown precursor to atrial fibrillation. 62 In a prospective study, LVH was found in up to 74% of 433 ESRD patients commencing dialysis. 43 Similar findings were replicated in another study carried out on non-diabetic pre-dialysis patients, which found that LVH was prevalent even in patients with a milder degree of kidney disease, with a prevalence of 51% in patients with CKD stages 1 and 2. 44 The mode of death of patients with advanced renal disease is atypical, with sudden death and progressive heart failure being more common, compared with classical myocardial infarction. Hence, strategic interventions focused at regressing LVH, which predisposes to sudden death in this cohort of people, may be of greater significance.
Treatments to target oxidative stress in patients with renal dysfunction
The above discussion strongly suggests that oxidative stress may have an important pathophysiological role in patients with renal disease. The fact that antioxidant vitamins work only in CKD/ESRD patients (Secondary Prevention with Antioxidants of Cardiovascular Disease in End-stage Renal Disease trial) also bolsters the idea that reversing oxidative stress may be a route worth exploring further in renal disease patients. [21] [22] [23] 63, 64 Moreover, use of oral and parenteral vitamin E has already been shown to improve renal anaemia and lessen the requirement of erythropoietin supplement in dialysis patients, 65 although another study has shown similar findings of improvement in haematocrit and reduced the need for erythropoietin supplementation with intravenous vitamin C. 66 Further studies have shown that oral vitamin E is able to attenuate oxidative stress induced by intravenous iron 67 and to significantly decrease the oxidative susceptibility of LDL in patients on renal replacement therapy. 68 Antioxidant-based dialysis membranes, such as vitamin E-modified cellulose membranes, have been shown to improve endothelial dysfunction and increase oxidised LDL. Recently, there have been promising reports of haemolipodialysis using vitamin E-containing liposomes and vitamin C in the dialysate to reduce the consequence of dialysis-induced oxidative stress, whereby the liposomes act as the 'radical sink' being oxidised and killed because of their high degree of unsaturation. 69 There may also be a role for N-acetylcysteine as an antioxidant, being relatively inexpensive and well tolerated.
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are highly effective inhibitors of angiotensin II-dependent NADPH oxidase activation, and have been used successfully in the clinical setting, especially in patients with CKD/ESRD. Although the beneficial effects of statins in CKD patients seem equivocal, especially when it has not been established in those with severe renal impairment, it is still worth exploring the use of statin as an anti-inflammatory agent. Studies in nonrenal patients suggest that a significant part of the benefit of statins, which inhibit the activation of small GTPases such as Rac1, thereby inhibiting NADPH oxidase, may be from its anti-inflammatory response, independent of its lipid-lowering effect.
Allopurinol is another potential candidate for reducing oxidative stress. George et al. 70 has shown that high-dose allopurinol can actually abolish oxidative stress in blood vessels in patients with congestive heart failure. In this study, high-dose allopurinol seemed to improve endothelial dysfunction and oxidative stress to a greater extent than exogenous antioxidant vitamins would. This is probably because allopurinol prevents the formation of these superoxide anions by inhibiting xanthine oxidase, although antioxidant vitamins merely try to mop up the excess free radicals that have formed. Furthermore, the rate constant between Vitamin C and superoxide anion is so low that enormous quantities of vitamin C would be required to adequately mop up superoxide anion.
Other ways of targeting the source of ROS, such as recoupling of NOS or enhancing intrinsic antioxidants, may be valuable, especially in reversing some of the clinical consequences of oxidative stress, such as cardiac remodelling. BH 4 and its precursor sepiapterin are currently used in the management of certain metabolic genetic diseases, -such as phenylketonuria, 71 and could be valuable in CKD. Even antioxidants such as high-dose vitamin C or a glutathione peroxidise mimetic may be useful because they reconvert BH 4 to the nonoxidised state, which leads to normalisation of NOS. Another possibility is to increase the synthesis of NO by administering high doses of L-arginine. This, however, would be difficult as L-arginine, which is normally given as a chloride salt, is an acidifying agent, which is probably contraindicated especially in advanced renal disease.
In summary, the role of oxidative stress in renal dysfunction is often underappreciated in clinical practice, but emerging evidence continues to highlight its strong correlation with cardiovascular morbidity and mortality. The two main adverse clinical consequences of oxidative stress are endothelial dysfunction and left ventricular hypertrophy. Therefore, new strategies in reversing both these adverse conditions by means of targeting oxidative stress by novel means are promising ways to improve the dire prognosis in CKD patients. They may be especially effective if used early in the course of renal disease before cardiovascular sequelae become irreversible or difficult to reverse.
